BR112018076169A2 - derivados azabenzimidazol como inibidores de pi3k beta - Google Patents

derivados azabenzimidazol como inibidores de pi3k beta

Info

Publication number
BR112018076169A2
BR112018076169A2 BR112018076169-9A BR112018076169A BR112018076169A2 BR 112018076169 A2 BR112018076169 A2 BR 112018076169A2 BR 112018076169 A BR112018076169 A BR 112018076169A BR 112018076169 A2 BR112018076169 A2 BR 112018076169A2
Authority
BR
Brazil
Prior art keywords
beta inhibitors
pi3k beta
azabenzimidazole derivatives
compounds
azabenzimidazole
Prior art date
Application number
BR112018076169-9A
Other languages
English (en)
Inventor
Noëlle Constance Pilatte Isabelle
Alexis Georges Querolle Olivier
René Angibaud Patrick
Jean-Claude Berthelot Didier
Coupa Sophie
Gabriel Marcel DEMESTRE Christophe
Meerpoel Lieven
Jean Maurice MERCEY Guillaume
Anne Mevellec Laurence
Meyer Christophe
Thérèse Jeanne Pasquier Elisabeth
Sophie Poncelet Virginie
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112018076169A2 publication Critical patent/BR112018076169A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

a presente invenção refere-se a derivados azabenzimidazol de fórmula (i) em que as variáveis têm o significado definido nas reivindicações. os compostos de acordo com a presente invenção são úteis como inibidores de pi3kß. a invenção refere-se ainda a composições farmacêuticas compreendendo os referidos compostos como ingrediente ativo, bem como o uso dos referidos compostos como um medicamento.
BR112018076169-9A 2016-06-16 2017-06-15 derivados azabenzimidazol como inibidores de pi3k beta BR112018076169A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16174712.6 2016-06-16
EP16174712 2016-06-16
PCT/EP2017/064672 WO2017216293A1 (en) 2016-06-16 2017-06-15 Azabenzimidazole derivatives as pi3k beta inhibitors

Publications (1)

Publication Number Publication Date
BR112018076169A2 true BR112018076169A2 (pt) 2019-03-26

Family

ID=56132833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076169-9A BR112018076169A2 (pt) 2016-06-16 2017-06-15 derivados azabenzimidazol como inibidores de pi3k beta

Country Status (13)

Country Link
US (1) US20190263804A1 (pt)
EP (1) EP3472147B1 (pt)
JP (1) JP7158286B2 (pt)
KR (1) KR102472198B1 (pt)
CN (1) CN109311843B (pt)
AU (1) AU2017286380B2 (pt)
BR (1) BR112018076169A2 (pt)
CA (1) CA3025746A1 (pt)
EA (1) EA037871B1 (pt)
ES (1) ES2818620T3 (pt)
IL (1) IL263653A (pt)
MX (1) MX2018015709A (pt)
WO (1) WO2017216293A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2965494T3 (es) 2018-04-12 2024-04-15 Bayer Ag Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}benzamida y los correspondientes derivados de piridina-carboxamida como plaguicidas
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
EP3784661B1 (en) 2018-04-25 2023-11-22 Bayer Aktiengesellschaft Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2021013719A1 (en) 2019-07-23 2021-01-28 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
CN110551101B (zh) * 2019-08-28 2020-11-24 沈阳药科大学 1、6-二取代-苯并五元杂环类衍生物及其用途
JP2022551309A (ja) 2019-10-09 2022-12-08 バイエル・アクチエンゲゼルシヤフト 殺有害生物剤としての新規ヘテロアリール－トリアゾール化合物
WO2021154668A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115151548A (zh) 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
WO2021154661A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20220132594A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
KR20220132592A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154663A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097103A1 (en) 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
US20230144824A1 (en) 2020-01-27 2023-05-11 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
MX2024010099A (es) * 2022-02-18 2024-08-28 Xizang Haisco Pharmaceutical Co Ltd Derivado de pirazolopiridina y aplicacion del mismo en medicina.
WO2024222880A1 (zh) * 2023-04-27 2024-10-31 西藏海思科制药有限公司 一种吡啶并吡唑衍生物的药物组合物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US20090170848A1 (en) 2006-03-02 2009-07-02 Smithkline Beecham Corporation Thiazolones for use as pi3 kinase inhibitors
US20090215818A1 (en) 2006-07-24 2009-08-27 Smithkline Beecham Corporation Thiozolidinedione derivatives as pi3 kinase inhibitors
WO2009021083A1 (en) 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
KR101701109B1 (ko) * 2007-10-05 2017-02-13 베라스템, 인코포레이티드 피리미딘 치환된 퓨린 유도체
SG187425A1 (en) 2008-01-04 2013-02-28 Intellikine Llc Certain chemical entities, compositions and methods
WO2011022439A1 (en) 2009-08-17 2011-02-24 Intellikine, Inc. Heterocyclic compounds and uses thereof
CN102741253A (zh) 2009-09-29 2012-10-17 艾科睿控股公司 PI3K(δ)选择性抑制剂
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP2624696B1 (en) 2010-10-06 2016-12-21 Glaxosmithkline LLC Benzimidazole derivatives as pi3 kinase inhibitors
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
US8778937B2 (en) 2011-12-20 2014-07-15 Glaxosmithkline Llc Benzimidazole boronic acid derivatives as PI3 kinase inhibitors
US8906910B2 (en) * 2011-12-20 2014-12-09 Glaxosmithkline Llc Imidazopyridine derivatives as PI3 kinase

Also Published As

Publication number Publication date
EP3472147A1 (en) 2019-04-24
JP2019518059A (ja) 2019-06-27
EP3472147B1 (en) 2020-06-17
WO2017216293A1 (en) 2017-12-21
KR102472198B1 (ko) 2022-11-28
CN109311843A (zh) 2019-02-05
CN109311843B (zh) 2021-10-08
JP7158286B2 (ja) 2022-10-21
ES2818620T3 (es) 2021-04-13
IL263653A (en) 2019-01-31
US20190263804A1 (en) 2019-08-29
KR20190016976A (ko) 2019-02-19
AU2017286380A1 (en) 2018-12-06
AU2017286380B2 (en) 2021-02-04
MX2018015709A (es) 2019-03-21
EA201892734A1 (ru) 2019-05-31
EA037871B1 (ru) 2021-05-28
CA3025746A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
BR112018003595A2 (pt) análogos de nucleosídeos substituídos no anel aromático 6-6 bicíclico para uso como inibidores de prmt5
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
BR112019006414A2 (pt) análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112012017442A2 (pt) derivados de triazol bicíclicos substituídos como moduladores de gamma secretase
BR112018005932A2 (pt) inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer
BR112016006651B8 (pt) compostos derivados de quinolizina substituídos, composição farmacêutica que os compreende e uso dos referidos compostos
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112015007183A2 (pt) composições, uso de uma composição, método para o combate dos fungos e semente
BR112013023984A2 (pt) derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112015022566A2 (pt) composto e composição farmacêutica
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta
UY35300A (es) Formulación de combinación de dos compuestos antivirales
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112018011525A2 (pt) inibidores da tirosina quinase de bruton e métodos de seu uso
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112015024971A2 (pt) derivados de n-(2,3-di-hidro-1h-pirrolo[2,3-b]piridin-5-il)-4-quinazolinamina e n-(2,3-di-hidro-1h-indol-5-il)-4-quinazolinamina como inibidores de perk
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]